Mark Currie

Mark G.
Currie currently works at Science Exchange, Inc., as Director from 2020, Antag Therapeutics ApS, as Director, Sea Pharmaceuticals LLC, as Director from 2021, Ironwood Pharmaceuticals, Inc., as Independent Director from 2019, and Iaso Ventures LP, as Partner.
Dr. Currie also formerly worked at Monsanto Co., as Director-Arthritis & Inflammation, G.D.
Searle & Co., Inc., as Director-Arthritis & Inflammation, Sumitomo Pharma America, Inc., as Vice President-Discovery Research from 1999 to 2002, Ironwood Pharmaceuticals, Inc., as Chief Scientific Officer, President-R&D, Senior VP from 2002 to 2019, and Cyclerion Therapeutics, Inc., as President & Chief Scientific Officer from 2019 to 2020.
Dr. Currie received his doctorate degree from Wake Forest School of Medicine and undergraduate degree from the University of South Alabama.